Supplemental material
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume 21, 2020 - Issue 7-8
Clinical & Biomarkers
The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis
Madeline Kelly1 Clinical Translational Medicine, Future Pipeline Discovery, GSK R&D, Hertfordshire, UK
https://orcid.org/0000-0001-6855-4550View further author information
https://orcid.org/0000-0001-6855-4550View further author information, Arseniy Lavrov2 Clinical Translational Medicine, Future Pipeline Discovery, GSK R&D, Middlesex, UKhttps://orcid.org/0000-0002-2360-2253View further author information
https://orcid.org/0000-0002-2360-2253View further author information, Luis Garcia-Gancedo3 Advanced Biostatistics and Data Analytics CoE, GSK, Hertfordshire, UKCorrespondence[email protected]
https://orcid.org/0000-0001-5631-1711View further author information
https://orcid.org/0000-0001-5631-1711View further author information, Jim Parr4 McLaren Applied Technologies, Surrey, UKhttps://orcid.org/0000-0001-5956-217XView further author information
https://orcid.org/0000-0001-5956-217XView further author information, Robert Hart4 McLaren Applied Technologies, Surrey, UKhttps://orcid.org/0000-0002-8507-3326View further author information
https://orcid.org/0000-0002-8507-3326View further author information, Theresa Chiwera5 United Kingdom Dementia Research Institute, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UKhttps://orcid.org/0000-0003-2884-4267View further author information
https://orcid.org/0000-0003-2884-4267View further author information, Christopher E. Shaw5 United Kingdom Dementia Research Institute, Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UKhttps://orcid.org/0000-0003-0251-0146View further author information
https://orcid.org/0000-0003-0251-0146View further author information, Ammar Al-Chalabi6 Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King’s College London, London, UK;7 Department of Neurology, King’s College Hospital, London, UKhttps://orcid.org/0000-0002-4924-7712View further author information
https://orcid.org/0000-0002-4924-7712View further author information, Rachael Marsden8 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UKhttps://orcid.org/0000-0003-0304-9427View further author information
https://orcid.org/0000-0003-0304-9427View further author information, Martin R. Turner8 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UKhttps://orcid.org/0000-0003-0267-3180View further author information
https://orcid.org/0000-0003-0267-3180View further author information & Kevin Talbot8 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UKhttps://orcid.org/0000-0001-5490-1697View further author information
https://orcid.org/0000-0001-5490-1697View further author information show all